PA-50/PA-41 antitoxin antibody therapy for C. difficile infection

PA-50/PA-41 抗毒素抗体治疗艰难梭菌感染

• 批准号: 8261683
• 负责人: WILLIAM C OLSON
• 金额: $ 112.85万
• 依托单位: PROGENICS PHARMACEUTICALS, INC.
• 依托单位国家: 美国
• 财政年份: 2011
• 资助国家: 美国
• 起止时间: 2011-05-01 至 2013-02-28
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/8261683
• 关键词: Address; Affect; Agreement; Amino Acids; Anaerobic Bacteria; Antibiotic Therapy; Antibiotics; Antibodies; Antibody Therapy; Antitoxins; Bacteria; Binding; Biology; Cell Line; Cessation of life; Clinical; Clinical Research; Clinical Trials; Clostridium difficile; Colitis; Colon; Comparative Study; Cytotoxin; Development; Diarrhea; Disease; Employee Strikes; Epidemic; Epitopes; Fluids and Secretions; Funding; Generations; Goals; Hamsters; Healed; Hospitalization; Hospitals; Human; In Vitro; Incidence; Individual; Infection; Inflammation; Intestines; Intoxication; Investigational New Drug Application; Large Intestine; Lead; Life; Mediating; Metronidazole; Microbe; Modeling; Molecular; Monoclonal Antibodies; New Agents; Oral; Patients; Pattern; Pharmacologic Substance; Positioning Attribute; Pre-Clinical Model; Recurrence; Relapse; Reproduction spores; Research Personnel; Resistance; Resolution; Role; Severities; Severity of illness; Specificity; Symptoms; TGFBI gene; Testing; Therapeutic; Time; Toxicology; Toxin; Translational Research; Universities; Vaccines; Vancomycin; Virulence Factors; Virulent; base; combat; design; factor C; global health; healing; human monoclonal antibodies; humanized monoclonal antibodies; illness length; improved; innovation; insight; manufacturing process; mortality; neutralizing monoclonal antibodies; novel; novel therapeutic intervention; overexpression; pre-clinical; preclinical study; prevent; public health relevance; research clinical testing; standard of care; success; treatment strategy

DESCRIPTION (provided by applicant): Clostridium difficile infection (CDI) is the leading cause both of hospital-acquired diarrhea and of death due to intestinal infections in the US. The incidence and severity of CDI have increased sharply over the past decade due in part to the emergence and worldwide spread of unusually virulent and deadly strains that overexpress two toxins, A and B. These potent cytotoxins represent the main virulence factors of C. difficile and can damage cells that line the colon, resulting in fluid secretion and inflammation. CDI typically is precipitated by the use of antibiotics, which disrupt the protective colonic flora and provide an opportunity for C. difficile to flourish. Treatment with oral vancomycin or metronidazole leads to symptom resolution in many patients; however, relapse occurs frequently. There is no standard therapy for multiply recurrent CDI or severe, life-threatening disease. Development of new treatment strategies is a global health imperative. One experimental treatment strategy is to neutralize the toxins with monoclonal antibodies (mAbs). Antitoxin mAbs represent a non-antibiotic therapy that is designed to block the harmful effects of the toxins while allowing the normal colonic flora to rebound and the colon to heal naturally. First-generation antitoxin mAbs have shown clinical activity in preventing recurrence of CDI but not in treating active disease. We have generated highly potent humanized mAbs, designated PA-50 and PA-41 that are directed to novel neutralization epitopes on toxins A and B, respectively. Compared with first-generation mAbs, PA-50 and PA-41 are 1,000-fold more potent in neutralizing toxins from virulent BI/NAP1/027 strains in vitro. In a well-established hamster model of CDI, treatment with PA-50/PA-41 provided long-term protection (95% survival) from a lethal challenge, whereas first-generation mAbs delayed but did not prevent death (0% survival). Highly potent mAbs like PA-50 and PA-41 have the potential both to break the cycle of infection in patients with multiply recurrent CDI and to treat life-threatening and otherwise challenging cases of CDI. The overall goal of this project is to complete preclinical studies of our lead mAbs and obtain agreement from FDA to initiate human testing. Initial preclinical studies will delineate the molecular and mechanistic underpinnings of the potent toxin-neutralizing activities of PA-50 and PA-41; these studies will also provide new insights into the biology of C. difficile intoxication. We also will examine the efficacy of the mAbs in treating active disease caused by BI/NAP1/027 strains in a newly established piglet model of CDI. Additional translational activities are designed to complete essential manufacturing, toxicology and other development activities required to prepare and submit Investigational New Drug applications (INDs) for PA-50 and PA-41. Success would ready PA-50 and PA-41 for human clinical testing and would constitute a key milestone in the development of innovative new agents that may address key challenges of the C. difficile epidemic. PUBLIC HEALTH RELEVANCE: Clostridium difficile is a spore-forming bacterium that represents the leading cause of hospital-acquired diarrhea and affects approximately 500,000 individuals annually in the US. Unusually deadly strains have emerged in recent years, and new treatments are urgently needed. C. difficile infection (CDI) typically strikes individuals who are taking antibiotics, which can disrupt the protective gut microbes and provide an opportunity for C. difficile to flourish. C. difficile produces toxins that can damage the cells that line the large intestines. One experimental treatment strategy is to block with harmful effects of the toxins with monoclonal antibodies. We have developed novel antibodies that potently neutralize C. difficile toxins in preclinical models of CDI. In this project, we seek to complete studies that will ready our antitoxin antibodies for clinical testing as non- antibiotic therapies for CDI.

描述（由申请人提供）：艰难梭菌感染（CDI）是美国医院获得性腹泻和肠道感染死亡的主要原因。CDI的发病率和严重程度在过去十年中急剧增加，部分原因是过度表达两种毒素A和B的异常毒性和致命菌株的出现和全球传播。这些强有力的细胞毒素代表了C.艰难梭菌，并能破坏结肠细胞，导致液体分泌和炎症。CDI通常是通过使用抗生素来加速的，抗生素破坏了保护性的结肠植物群，为C.难以绽放。口服万古霉素或甲硝唑治疗导致许多患者的症状消退;然而，复发频繁发生。对于多次复发的CDI或严重的危及生命的疾病，没有标准的治疗方法。开发新的治疗策略是全球卫生的当务之急。一种实验性治疗策略是用单克隆抗体（mAb）中和毒素。抗毒素单克隆抗体代表了一种非抗生素疗法，旨在阻断毒素的有害影响，同时允许正常结肠植物群反弹和结肠自然愈合。第一代抗毒素mAb在预防CDI复发方面显示出临床活性，但在治疗活动性疾病方面没有。 我们已经产生了高效的人源化mAb，命名为PA-50和PA-41，其分别针对毒素A和B上的新中和表位。与第一代mAb相比，PA-50和PA-41在体外中和BI/NAP 1/027强毒株毒素的效力高1，000倍。在一个成熟的CDI仓鼠模型中，PA-50/PA-41治疗提供了长期保护（95%存活率），免于致死性攻击，而第一代mAb延迟但不能预防死亡（0%存活率）。PA-50和PA-41等高效mAb有可能打破多次复发CDI患者的感染循环，并治疗危及生命和其他具有挑战性的CDI病例。该项目的总体目标是完成我们的主要mAb的临床前研究，并获得FDA的同意，以启动人体试验。初步的临床前研究将描述PA-50和PA-41的强效毒素中和活性的分子和机制基础;这些研究还将为C.艰难中毒我们还将在新建立的CDI仔猪模型中检查mAb治疗BI/NAP 1/027菌株引起的活动性疾病的疗效。其他翻译活动旨在完成准备和提交PA-50和PA-41的研究性新药申请（IND）所需的基本生产、毒理学和其他开发活动。成功将使PA-50和PA-41为人类临床试验做好准备，并将成为开发创新新药物的关键里程碑，这些药物可能会解决C.艰难的流行病 公共卫生相关性：艰难梭菌是一种孢子形成细菌，是医院获得性腹泻的主要原因，在美国每年影响约50万人。近年来出现了异常致命的菌株，迫切需要新的治疗方法。C.艰难梭菌感染（CDI）通常会袭击正在服用抗生素的人，这会破坏保护性肠道微生物，并为C。难以绽放。C.艰难梭菌产生的毒素会破坏大肠细胞。一种实验性治疗策略是用单克隆抗体阻断毒素的有害作用。我们已经开发出了新的抗体，可以有效地中和C。艰难梭菌毒素在CDI的临床前模型中的作用。在这个项目中，我们寻求完成研究，准备我们的抗毒素抗体作为CDI的非抗生素疗法进行临床测试。